Marco Sacco, Federica Mediati, Pietro Palmieri, Stefania Caronna, Chiara Giordanino, Milena Marietti, Chiara Manuli, Mauro Bruno, Silvia Gaia, Claudio Giovanni De Angelis
{"title":"Age-related outcomes of digital single-operator cholangio-pancreatoscopy: a single-center retrospective study.","authors":"Marco Sacco, Federica Mediati, Pietro Palmieri, Stefania Caronna, Chiara Giordanino, Milena Marietti, Chiara Manuli, Mauro Bruno, Silvia Gaia, Claudio Giovanni De Angelis","doi":"10.1097/MEG.0000000000003230","DOIUrl":"10.1097/MEG.0000000000003230","url":null,"abstract":"<p><strong>Background: </strong>Digital single-operator cholangiopancreatoscopy (DSOC) is an important adjunct to endoscopic retrograde cholangiopancreatography (ERCP) for the diagnosis and treatment of complex biliary and pancreatic diseases. However, data regarding its safety and efficacy in elderly patients remain limited.</p><p><strong>Aim: </strong>To evaluate the safety and efficacy of DSOC in patients aged 75 years compared with a younger population.</p><p><strong>Methods: </strong>We retrospectively analyzed consecutive patients who underwent ERCP with DSOC at a tertiary referral center between January 2017 and July 2025. Patients were stratified according to age (≥75 vs. <75 years). The primary outcome was procedure-related adverse events, defined according to American Society for Gastrointestinal Endoscopy criteria. Secondary outcomes included technical and clinical success rates and factors associated with complications.</p><p><strong>Results: </strong>A total of 136 patients underwent 170 DSOC procedures. Elderly patients had more comorbidities and higher American Society of Anesthesiologists scores compared with younger patients. Overall adverse event rates were comparable between elderly and younger patients (8 vs. 13%; P = 0.44), while technical and clinical success rates were high in both groups. Multivariate analysis showed that age was not independently associated with adverse events.</p><p><strong>Conclusion: </strong>In this retrospective single-center study, DSOC was feasible in selected elderly patients, with complication rates and procedural outcomes comparable to those of younger individuals. The lack of formal frailty assessment and procedural burden metrics limits generalizability to frail or unselected elderly populations. In this retrospective single-center study, DSOC was feasible in selected elderly patients, with complication rates and procedural outcomes comparable to those of younger individuals. The lack of formal frailty assessment and procedural burden metrics limits generalizability to frail or unselected elderly populations.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1382-1387"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jing-Ming Zhang, Xuan Zhang, Yi-Jin Zhang, Jie Chen, Shu-Jun Li, Mei-Mei Wu, Bian-Qiao Cheng
{"title":"Prognostic value of systemic inflammatory markers for disease severity and mortality in cirrhosis: a MIMIC-IV-based cohort study.","authors":"Jing-Ming Zhang, Xuan Zhang, Yi-Jin Zhang, Jie Chen, Shu-Jun Li, Mei-Mei Wu, Bian-Qiao Cheng","doi":"10.1097/MEG.0000000000003289","DOIUrl":"10.1097/MEG.0000000000003289","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to investigate the associations between systemic inflammatory markers and disease severity and mortality in patients with cirrhosis and to identify robust prognostic indicators.</p><p><strong>Methods: </strong>Data from 2940 cirrhotic patients were obtained from the MIMIC-IV database(version 2.2). Generalized ordered logistic regression evaluated determinants of cirrhosis severity. Associations between inflammatory markers and mortality were examined using Cox proportional hazards models. Restricted cubic splines and two-piecewise Cox models were employed to explore nonlinear and threshold effects.</p><p><strong>Results: </strong>With increasing Child-Turcotte-Pugh class, inflammatory markers including neutrophil-to-lymphocyte ratio (NLR) and neutrophil-to-platelet ratio (NPR) increased progressively, whereas lymphocyte counts decreased. After collinearity assessment, aspartate aminotransferase-to-platelet ratio index, NPR, NLR, age, and Simplified Acute Physiology Score were retained for multivariable analyses. In multivariable Cox regression, NPR emerged as an independent predictor of mortality, with each unit increase in NPR associated with a higher risk of 28-day mortality [hazard ratio = 1.55, 95% confidence interval (CI)= 1.30-1.84; P < 0.001] and 365-day mortality (hazard ratio = 1.31, 95% CI = 1.18-1.46; P < 0.001). Analyses demonstrated a significant J-shaped association between NPR and mortality, with a consistent inflection point at NPR = 0.05, above which mortality risk markedly increased.</p><p><strong>Conclusion: </strong>NPR independently predicts short- and long-term all-cause mortality in cirrhosis, exhibiting a clinically meaningful nonlinear threshold relationship. These findings emphasize the role of systemic inflammation in cirrhosis progression and highlight NPR as a practical biomarker for clinical risk stratification.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1433-1442"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on 'Cardiovascular risk profiles in patients with primary sclerosing cholangitis'.","authors":"Yavuz Emre Parlar","doi":"10.1097/MEG.0000000000003271","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003271","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 12","pages":"1464"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Connor E M Cotton, Arkadeep Dhali, Cristina Caranfil, Peter Evans, Beth Brailsford, Greg Naylor, David S Sanders
{"title":"Pancreatic enzyme replacement therapy in pancreatic exocrine insufficiency: what about luminal disease?","authors":"Connor E M Cotton, Arkadeep Dhali, Cristina Caranfil, Peter Evans, Beth Brailsford, Greg Naylor, David S Sanders","doi":"10.1097/MEG.0000000000003282","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003282","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 12","pages":"1467"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Portal venous system thrombosis after cyanoacrylate injection for gastric varices under endoscopic ultrasound versus conventional endoscopy: a propensity-matched study.","authors":"Yingying He, Zhihong Wang, Yuxin Liao, Wanyu Ma, Xu Yang, Derun Kong","doi":"10.1097/MEG.0000000000003308","DOIUrl":"10.1097/MEG.0000000000003308","url":null,"abstract":"<p><strong>Objective: </strong>To compare the incidence of portal venous system thrombosis (PVST) following endoscopic ultrasound-guided cyanoacrylate injection (EUS-CYA) versus direct endoscopic cyanoacrylate injection (DEI-CYA) for gastric varices, and to identify associated risk factors.</p><p><strong>Methods: </strong>A total of 202 patients with cirrhosis who underwent either EUS-CYA or DEI-CYA for gastric varices were retrospectively enrolled. All patients were followed for at least 1 year after the procedure, and early PVST was assessed 3-5 months post-procedure. Propensity score matching was performed to balance baseline characteristics. The early and overall incidence of PVST was compared between groups, and an extended Cox proportional hazards model was used to identify risk factors.</p><p><strong>Results: </strong>After matching, 132 patients were included (66 per group). The incidence of post-procedural early PVST was significantly higher in the EUS-CYA group than in the DEI-CYA group (16.7% vs. 4.5%, hazard ratio = 3.62, P = 0.035), while overall PVST during follow-up showed no difference (22.7% vs. 16.7%, P = 0.340). Cumulative endoscopic treatment sessions [hazard ratio = 1.98, 95% confidence interval (CI) = 1.36-2.89, P < 0.001], D-dimer (hazard ratio = 1.10, 95% CI = 1.02-1.20, P = 0.015), and white blood cell count (hazard ratio = 0.87, 95% CI = 0.77-0.98, P = 0.024) were independently associated with PVST.</p><p><strong>Conclusion: </strong>EUS-CYA was associated with an increased risk of early PVST. Enhanced imaging surveillance, particularly 90-130 days after the procedure, is warranted. Cumulative endoscopic treatment sessions, D-dimer, and white blood cell count are independently associated with the development of PVST.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1455-1463"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diogo Couto Sousa, Samuel Raimundo Fernandes, André Da Silva Neves, Filipa Pereira, Sérgio Bronze, Inês Coelho Rodrigues, Sofia Saraiva, Ana Rita Gonçalves, Ana Valente, Luís Correia
{"title":"External validation of a prediction score for identifying a mild course of Crohn's disease.","authors":"Diogo Couto Sousa, Samuel Raimundo Fernandes, André Da Silva Neves, Filipa Pereira, Sérgio Bronze, Inês Coelho Rodrigues, Sofia Saraiva, Ana Rita Gonçalves, Ana Valente, Luís Correia","doi":"10.1097/MEG.0000000000003242","DOIUrl":"10.1097/MEG.0000000000003242","url":null,"abstract":"<p><strong>Introduction: </strong>Crohn's disease has a heterogeneous course. Early identification of patients likely to follow a mild trajectory remains challenging. The prediction score for a mild course of Crohn's disease (PreMiCC) was recently proposed, but external validation is lacking.</p><p><strong>Methods: </strong>This single-center retrospective study included patients diagnosed with Crohn's disease between 2004 and 2024. The PreMiCC score was calculated at diagnosis using the original variables: age, C-reactive protein, perianal disease, endoscopic severity, and complications. Patients were classified as having a score ≤2 or >2. Outcomes included mild disease course, need for biologic therapy, Crohn's disease-related surgery or hospitalization, and time to treatment escalation.</p><p><strong>Results: </strong>A total of 342 patients (51% male; mean age 35 ± 16 years) were included, with a mean follow-up of 9 ± 5 years. At diagnosis, 55% had a PreMiCC score ≤2. A mild disease course occurred in 31% of patients and was more common in those with a score ≤2 than >2 (42% vs. 17%; P < 0.001). Patients with a score >2 more frequently required biologic therapy (80% vs. 54%; P < 0.001) and hospitalization (15% vs. 7%; P = 0.023), whereas the need for surgery did not differ between groups (20% vs. 17%; P = 0.415). The PreMiCC score independently predicted biologic therapy [odds ratio = 1.65, 95% confidence interval (CI) = 1.33-2.04; P < 0.001]. Time to treatment escalation was shorter in patients with a score >2 (log-rank P < 0.001). The model showed acceptable discrimination (area under the receiver operating characteristic curve = 0.708, 95% CI = 0.649-0.768), with 74% sensitivity, 55% specificity, 42% positive predictive value, and 83% negative predictive value.</p><p><strong>Conclusion: </strong>This first external validation confirms the predictive value of the PreMiCC score in a real-world cohort, supporting its use as a simple tool for early risk stratification in Crohn's disease.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1407-1412"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic plasma exchange improves survival in alcohol-related acute-on-chronic liver failure: a randomized controlled trial.","authors":"Manasvin Sareen, Prabhat Narain Sharma, Sudhir Maharshi, Kamlesh Kumar Sharma, Vijayant Tak, Sandeep Nijhawan, Rupesh Pokharna, Shyam Sunder Sharma, Gurjot Singh, Vinay Malhotra","doi":"10.1097/MEG.0000000000003287","DOIUrl":"10.1097/MEG.0000000000003287","url":null,"abstract":"<p><strong>Objectives: </strong>Acute-on-chronic liver failure (ACLF) is associated with high short-term mortality and limited therapeutic options. Therapeutic plasma exchange (PLEX) may improve outcomes by removing inflammatory mediators, but randomized evidence in ACLF is limited. This study evaluated the efficacy of PLEX in alcohol-related ACLF (A-ACLF).</p><p><strong>Methods: </strong>In this randomized controlled trial, 100 patients with A-ACLF were randomized (1 : 1) to PLEX plus standard medical therapy (SMT) or SMT alone. PLEX was performed for up to three sessions. Coprimary outcomes were in-hospital mortality and 30-day survival. Secondary outcomes included hospital stay, ventilator requirement, and longitudinal changes in disease severity scores and laboratory parameters.</p><p><strong>Results: </strong>All 100 patients (PLEX n = 50; SMT n = 50) completed follow-up. In-hospital mortality was lower with PLEX [24 vs. 52%; P = 0.007], with an absolute risk reduction of 28% (number needed to treat: 3.6). Thirty-day survival was higher with PLEX (72 vs. 36%; P < 0.001), with an adjusted hazard ratio for mortality of 0.43 (P = 0.003). Significant improvements were observed in the model for end-stage liver disease sodium, Asian Pacific Association for the Study of the Liver ACLF Research Consortium, and Child-Turcotte-Pugh scores, and in international normalized ratio, creatinine, lactate, ammonia, and von Willebrand factor (all P < 0.001 for interaction). Hospital stay was shorter with PLEX (19 vs. 24 days; P = 0.023). No major PLEX-related adverse events were observed.</p><p><strong>Conclusion: </strong>PLEX improves short-term survival and disease severity in A-ACLF and may be a valuable therapeutic option where transplantation is limited.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 12","pages":"1413-1422"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"M echanisms of symptom generation in patients with lactose intolerance: lessons learned from validated symptom assessment during lactose breath tests.","authors":"Johann Hammer, Heinz F Hammer","doi":"10.1097/MEG.0000000000003235","DOIUrl":"10.1097/MEG.0000000000003235","url":null,"abstract":"<p><strong>Background: </strong>Lactose intolerance is a common cause of functional gastrointestinal symptoms. Traditional diagnostic strategies primarily focus on detecting malabsorption despite symptoms often occurring without it.</p><p><strong>Objectives: </strong>This study examined the role of malabsorption and nonmalabsorptive mechanisms in the development of symptoms in patients with lactose intolerance.</p><p><strong>Design: </strong>We analyzed 1015 patients undergoing standardized 50-g lactose hydrogen (H 2 ) breath testing with simultaneous symptom assessment using the adult Carbohydrate Perception Questionnaire. Malabsorption was defined as an H 2 increase greater than 20 ppm, and intolerance as a ≥ 20- and 35-mm increase in symptom scores. Breath test parameters and symptom patterns were compared across four groups: symptomatic malabsorbers (S+/M+), asymptomatic malabsorbers (S-/M+), symptomatic nonmalabsorbers or symptomatic absorbers (S+/M-), and asymptomatic nonmalabsorbers or asymptomatic absorbers (S-/M-). Linear and multiple regressions and receiver operating characteristic (ROC) analyses evaluated associations between H 2 kinetics and symptoms.</p><p><strong>Results: </strong>Symptoms occurred frequently both with and without malabsorption: 267 (S+/M+) and 236 (S+/M-). S+/M+ patients showed higher maximal H 2 (98 vs. 59 ppm), larger area under the ROC curve (AUC) H 2 , and faster H 2 accumulation than S-/M+ (all P < 0.001). Symptom burdens were higher in S+/M+ than S+/M- (133 vs. 72 mm; P < 0.001). However, H 2 increases explained only 22% of symptom variance. In regression models, flatulence, pain, and diarrhea independently predicted malabsorption, while bloating and nausea did not. ROC performance was modest for both H 2 (AUC: 0.66) and symptoms (AUC: 0.70).</p><p><strong>Conclusion: </strong>Lactose-induced symptoms arise through two partially independent mechanisms: a malabsorptive colonic fermentation pathway and a nonmalabsorptive pathway. Breath testing alone is insufficient to identify clinically relevant lactose intolerance; integrating physiological and symptom-based measures provides a more accurate mechanistic understanding.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1388-1397"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Allostatic load, unhealthy behaviors, and mortality risk among participants with and without metabolic dysfunction-associated steatotic liver disease.","authors":"Dongzhi Hong, Bin Xi, Zuopei Lv, Nannan Li, Xinyu He, Xinyi Zhu, Jianan Zhang, Chenxing Wang, Zhenzhai Cai, Hao Wu, Beilei Fu","doi":"10.1097/MEG.0000000000003290","DOIUrl":"10.1097/MEG.0000000000003290","url":null,"abstract":"<p><strong>Background: </strong>Chronic stress and unhealthy behaviors are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). However, whether and to what extent they are associated with mortality across different stages of MASLD remains unclear. This study aimed to examine the associations of allostatic load and unhealthy behaviors with mortality according to MASLD stage.</p><p><strong>Methods: </strong>The study included 9761 participants from the National Health and Nutrition Examination Survey (2005-2018). MASLD was defined as hepatic steatosis with at least one cardiometabolic criterion. Allostatic load, an indicator of chronic stress, was assessed using 10 biomarkers. Health behaviors included diet, nicotine exposure, physical activity, and sleep duration. Cox proportional hazards models estimated the associations of allostatic load and health behavior score (HBS) with mortality.</p><p><strong>Results: </strong>Among 9761 participants, 3158 (32.4%) were classified as having MASLD. During a median follow-up of 7.42 years, 922 participants died, including 268 cardiovascular deaths. Allostatic load and HBS were associated with all-cause and cardiovascular mortality among participants with and without MASLD. The combination of high allostatic load and poor HBS was associated with higher risks of all-cause and cardiovascular mortality, particularly among participants with MASLD [hazard ratio = 3.33, 95% confidence interval (CI) = 1.97-5.65 for all-cause mortality; hazard ratio = 3.66, 95% CI = 1.31-10.23 for cardiovascular mortality].</p><p><strong>Conclusion: </strong>Higher allostatic load and poorer health behaviors were independently and jointly associated with higher risks of all-cause and cardiovascular mortality among participants with and without MASLD. These findings highlight the importance of chronic stress and poor health behaviors in MASLD management and prognosis.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"1443-1454"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}